Sanofi SA announced on Thursday that its net sales in the fourth quarter of the fiscal year 2024 observed an annual rise of 9.1%, 10.3% at the constant exchange rate (CER), to reach €10.56 billion.
The company's net income, calculated according to the International Financial Reporting Standards (IFRS), came in at €683 million, and its IFRS earnings per share (EPS) at €0.54. Meanwhile, its business net income declined by 15.1%, or 11.2% at CER, to €1.64 million, and its business EPS by 14.9%, 11.0% at CER, to €1.31. In the entire fiscal year 2024, Sanofi's net sales increased by 8.6%, 11.3% at CER, to €41.1 billion.
"As we enter 2025, we expect continued, solid growth in sales and a strong rebound in earnings. We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches ... and expected future launches from our pipeline," Chief Executive Officer (CEO) Paul Hudson said.